13 completed, 1 recruiting. 14 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 13, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Placebo single dose: new trials by email Literature Review of Placebo single dose trials Research Report on Placebo single dose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency Intranasal Oxytocin (IN-OXT) 6 IU single dose, Intranasal Oxytocin (IN-OXT) 6 IU repeat dose, Placebo repeat dose - Vasopressin Deficiency | Phase 1 | Recruiting | Elizabeth Austen Lawson | 40 | 2025-09-10 | 2026-10-26 |
| To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects BAR502 single dose, Placebo single dose, BAR502 multiple doses - NASH | Phase 1 | Completed | BAR Pharmaceuticals s.r.l. | 43 | 2024-12-04 | 2026-09-21 |
| A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly Participants DA-7503 Single dose, DA-7503 Multiple dose, Placebo Single dose - Healthy | Phase 1 | Completed | Dong-A ST Co., Ltd. | 90 | 2024-05-27 | 2026-05-22 |
| A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects ETD001 single dose, Placebo single dose, ETD001 multiple twice daily doses - Cystic Fibrosis | Phase 1 | Completed | Enterprise Therapeutics Ltd | 98 | 2021-06-11 | 2022-03-24 |
| Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male BBT-877 single dose, Placebo single dose - Healthy Participants | Phase 1 | Completed | Bridge Biotherapeutics, Inc. | 24 | 2019-10-01 | 2020-01-18 |
| Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) BION-1301 Single Dose, Placebo Single Dose, BION-1301 Multiple Doses - IgA Nephropathy | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 103 | 2019-04-08 | 2026-06-16 |
| A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics. HNC042 single dose, Placebo single dose, HNC042 multiple ascending doses - Healthy | Phase 1 | Completed | Guangzhou Henovcom Bioscience Co. Ltd. | 74 | 2018-11-09 | 2019-09-19 |
| A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects. GLPG3067 single dose, Placebo single dose, GLPG3067 multiple dose - Healthy | Phase 1 | Completed | Lakefront Biotherapeutics NV | 81 | 2017-03-28 | 2018-04-10 |
| A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects GLPG2737 single dose, Placebo single dose, GLPG2737 multiple dose - Healthy | Phase 1 | Completed | Lakefront Biotherapeutics NV | 79 | 2016-11-25 | 2018-01-25 |
| Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979. PF-06751979 single dose, Placebo single dose, PF-06751979 multiple ascending dose - Healthy Subjects | Phase 1 | Completed | Pfizer | 46 | 2016-06-13 | 2018-09-17 |
| First-in-Human Single and Multiple Dose of GLPG2222 GLPG2222 single dose, Placebo single dose, GLPG2222 multiple doses - Healthy | Phase 1 | Completed | Lakefront Biotherapeutics NV | 40 | 2016-01-01 | 2016-07-29 |
| First-in-Human Single and Multiple Dose of GLPG1972 GLPG1972 single ascending doses, Placebo single dose, GLPG1972 multiple ascending doses - Healthy | Phase 1 | Completed | Lakefront Biotherapeutics NV | 41 | 2015-11-01 | 2016-07-29 |
| First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979 PF-06751979 single ascending dose, Placebo single dose, PF-06751979 multiple ascending dose - Healthy Subjects | Phase 1 | Completed | Pfizer | 55 | 2015-07-01 | 2018-11-01 |
| First-in-Human Single and Multiple Dose of GLPG1837 GLPG1837 single ascending doses, Placebo single dose, GLPG1837 multiple ascending doses - Healthy | Phase 1 | Completed | Lakefront Biotherapeutics NV | 64 | 2014-12-01 | 2015-09-09 |
Alzheimer Disease (2) · Anxiety Disorders (1) · Cystic Fibrosis (1) · Depression (1) · Diabetes Insipidus, Neurogenic (1) · Glomerulonephritis, IGA (1) · Hypopituitarism (1) · Non-alcoholic Fatty Liver Disease (1)
Lakefront Biotherapeutics NV (5) · Pfizer (2) · BAR Pharmaceuticals s.r.l. (1) · Bridge Biotherapeutics, Inc. (1) · Dong-A ST Co., Ltd. (1) · Elizabeth Austen Lawson (1) · Enterprise Therapeutics Ltd (1) · Guangzhou Henovcom Bioscience Co. Ltd. (1) · Novartis Pharmaceuticals (1)
Belgium (5) · United States (5) · South Korea (2) · United Kingdom (2) · Netherlands (1) · Switzerland (1)
Chris Brearley, BM, MRCP, MFPM (1) · Elizabeth A Lawson, MD, MMSc (1) · Ennis Lee, MD (1) · Jeong-Hyun Ryou, M.D., Ph.D. (1) · Kirsteen Donaldson, MD (1) · Magdalena Petkova, MD (1) · Milko Radicioni, MD (1) · Niyati Prasad, MD (1)
2015 (2), 2016 (2), 2014 (1), 2018 (1)